Privo Technologies, Inc.  attends the BIO International Convention online from June 14-18, 2021. Despite the conference being held online this year... read more

Privo Technologies is honored to receive a Phase 1 award for $220,000 from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more

Privo Technologies Inc., a pioneering biopharmaceutical company known for its innovative approach to drug delivery and cancer treatment, is proud... read more

Peabody, MA-- Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

  Privo Technologies is proud to announce the receipt of $4.5 million in funding from the National Cancer Institute to support... read more

Privo Technologies, Inc. is pleased to announce that it has received IRB approval for its CLN-004 study from WCG... read more

PEABODY, Mass., Aug. 24, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo"), a phase 3 clinical stage biopharmaceutical company that has designed... read more

Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment... read more

​​​​​Privo Technologies (Privo) has been selected for the prestigious Phase IIB Bridge Award from the National Cancer Institute (NCI). The NCI SBIR... read more

Watch Dr. Goldberg's presentation below regarding localized treatment of cancers in a more safe and effective way and the positive... read more